Resources from the same session
2933 - Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.
Presenter: Karim Fizazi
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Proffered paper session - Genitourinary tumours, prostate - Invited Discussant 791O
Presenter: Eleni Efstathiou
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
2672 - ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Matthew Smith
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Proffered paper session - Genitourinary tumours, prostate - Invited Discussant LBA30
Presenter: Daniel Heinrich
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
1576 - A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Kim Chi
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast